Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Cancers Année : 2023

Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients

1 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
2 IGR - Institut Gustave Roussy
3 AMMICa - Analyse moléculaire, modélisation et imagerie de la maladie cancéreuse
4 Institut Curie [Paris]
5 Hôpital Avicenne [AP-HP]
6 Université Sorbonne Paris Nord
7 Hôpital Ambroise Paré [AP-HP]
8 Université Paris-Saclay
9 BECCOH - Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
10 Service des Maladies de l'Appareil Digestif et de la Nutrition [CHRU Lille]
11 ONCO-THAI - Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189
12 INCIT - Immunology and New Concepts in ImmunoTherapy
13 CHU Nantes - Centre Hospitalier Universitaire de Nantes = Nantes University Hospital
14 CIC Nantes - Centre d’Investigation Clinique de Nantes
15 Service d'immunologie clinique et maladies infectieuses [Hôpitaux universitaires CHU Henri Mondor]
16 CHRU Tours - Centre Hospitalier Régional Universitaire de Tours
17 Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois]
18 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
19 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
20 EFS BFC - Etablissement français du sang [Bourgogne-Franche-Comté]
21 Centre Hospitalier Le Mans (CH Le Mans)
22 Centre Léon Bérard [Lyon]
23 UPCité - Université Paris Cité
24 CIC Hôpital Bichat
25 CRCM - Centre de Recherche en Cancérologie de Marseille
26 TIMONE - Hôpital de la Timone [CHU - APHM]
27 AP-HP - Hopital Saint-Louis [AP-HP]
28 HIPI (UMR_S_976 / U976) - Immunologie humaine, physiopathologie & immunothérapie
Sarah Mezghani
Lorry Hachon
  • Fonction : Auteur

Résumé

Data regarding elderly melanoma patients treated with anti-PD-1 or anti-CTLA-4 antibodies are in favor of tolerability outcomes that are similar to those of younger counterparts. However, there are very few studies focusing on elderly patients receiving nivolumab combined with ipilimumab (NIVO + IPI). Here, we ask what are the current prescribing patterns of NIVO + IPI in the very elderly population and analyze the tolerance profile. This French multicenter retrospective study was conducted on 60 melanoma patients aged 80 years and older treated with NIVO + IPI between January 2011 and June 2022. The mean age at first NIVO + IPI administration was 83.7 years (range: 79.3–93.3 years). Fifty-five patients (92%) were in good general condition and lived at home. Two dosing regimens were used: NIVO 1 mg/kg + IPI 3 mg/kg Q3W (NIVO1 + IPI3) in 27 patients (45%) and NIVO 3 mg/kg + IPI 1 mg/kg Q3W (NIVO3 + IPI1) in 33 patients (55%). NIVO + IPI was a first-line treatment in 39 patients (65%). The global prevalence of immune-related adverse events was 63% (38/60), with 27% (16/60) being of grade 3 or higher. Grade ≥ 3 adverse events were less frequent in patients treated with NIVO3 + IPI1 compared with those treated with NIVO1 + IPI3 (12% versus 44%, p = 0.04). In conclusion, the prescribing patterns of NIVO + IPI in very elderly patients are heterogeneous in terms of the dosing regimen and line of treatment. The safety profile of NIVO + IPI is reassuring; whether or not the low-dose regimen NIVO3 + IPI1 should be preferred over NIVO1 + IPI3 in patients aged 80 years or older remains an open question.

Dates et versions

inserm-04202964 , version 1 (11-09-2023)

Identifiants

Citer

Constance Reichert, Capucine Baldini, Sarah Mezghani, Eve Maubec, Christine Longvert, et al.. Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients. Cancers, 2023, 15 (17), pp.4330. ⟨10.3390/cancers15174330⟩. ⟨inserm-04202964⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More